At this year’s ASCO annual meeting, CRC management insights were revealed in several abstract presentations covering pembrolizumab, regorafenib, immunotherapies, trifluridine/tipiracil plus bevacizumab, and an antibody-drug conjugate targeting HER2.
Review Publication: Hematology AdvisorDesign: At the Annual Meeting of the Society of Hematologic Oncology, researchers presented a study identifying a higher percentage of patients with germline predisposition syndromes (GPS).Results: Following a review of medical records of patients diagnosed with GPS between 1994 and 2018, the investigators reported that the detection of GPS positively impacted medical […]
From the pages of Clinical Advances in Hematology & Oncology comes this review of selected presentations from the 2021 TCT Meetings Digital Experience, which took place February 8-12, 2021. Expert commentary is provided by Dr. Yi-Bin Chen, Director of the Hematopoietic Cell Transplant & Cellular Therapy Program at Massachusetts General Hospital.
According to research presented at the virtual ASCO GI Cancers Symposium from the phase 3 ALTER0703 trial, anlotinib was beneficial in Chinese patients with refractory metastatic colorectal cancer (CRC), with particular overall survival (OS) improvement – the primary endpoint – among patients with RAS/KRAS/BRAF-wildtype.
Clinical Advances in Hematology & Oncology presents a review of selected presentations from the 2020 SABCS Virtual Symposium, which took place in December 2020. Expert commentary is provided by Joyce A. O’Shaughnessy, MD of Baylor University Medical Center and the Director of the Breast Cancer Research Program, Texas Oncology, US Oncology, in Dallas.
This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results from various trials and studies, including MEDALIST, DACOTA, P-2001, M15-531, ACE-536-MF-001, Sintra-REV, and COMMANDS.
This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others.
The possible answer was presented during the 2020 ASH Annual Meeting, bringing into question whether current recommendations for prophylactic intravenous high-dose methotrexate — the most widely adopted method for CNS relapse prevention — are appropriate for all patients at high risk of a CNS relapse.
This review and commentary from the ESMO Virtual Congress 2020 features a look at the following trials: ASCENT (sacituzumab govitecan-hziy), IMpassion130 (atezolizumab + nab-paclitaxel), IMpassion131 (first-line paclitaxel +/– atezolizumab), IPATunity130 (ipatasertib + paclitaxel), SEASTAR (rucaparib + sacituzumab govitecan), FLIPPER (fulvestrant/palbociclib), SOLAR-1 (alpelisib + fulvestrant), and FURVA (vandetanib + fulvestrant).
The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.